ELDN250117C10000
- 0.00
- 0.000.00%
Eledon Pharmaceuticals Newsroom
Eledon Pharma Analyst Ratings
H.C. Wainwright Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $16
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN)
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Market Cap Dropped US$57m Last Week; Individual Investors Who Hold 57% Were Hit as Were Institutions
Eledon Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Ladenburg Thalmann Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Cuts Target Price to $20.5
Eledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy Rating
Eledon Pharmaceuticals GAAP EPS of -$0.32 Misses by $0.02
Eledon Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Eledon Pharmaceuticals | 8-K: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals 3Q Net $77M >ELDN
Eledon Pharmaceuticals Sees Cash Runway to End of 2026 >ELDN
Press Release: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Express News | Eledon Pharmaceuticals Q3 Operating Expenses USD 20.51 Million
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
12 Health Care Stocks Moving In Wednesday's After-Market Session
Leerink Partners Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $9
Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise
Express News | Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants